PLX READ THE FULL PLX RESEARCH REPORT Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO ...

Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the discovery, development, production and ...

Local leaders, students and others in San Jose, California, were stunned when a photograph of high school students forming a ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Here’s a summary of the most significant insider transactions disclosed on Tuesday for U.S. publicly traded companies. Top ...

The average one-year price target for Protalix BioTherapeutics (NYSEAM:PLX) has been revised to $12.75 / share. This is a decrease of 10.71% from the prior estimate of $14.28 dated November 14, 2025.

BioMarin Pharmaceutical’s strong rare disease drug portfolio and Amicus acquisition drive a ‘Buy’ rating. Click here to read my latest analysis of BMRN stock.

After a brief pause, gold is back on the rise. On Tuesday, it climbed above the $4,300 per ounce mark again, partly thanks to the weakness of the US dollar. When might we see new ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...